CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Zöller, Margot ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adhesion; Apoptosis resistance; Bone marrow niche; CD44; Dormancy; Hematopoietic stem cells; Homing; Leukemia initiating cells

Indexed keywords

CATHEPSIN G; GELATINASE A; GELATINASE B; HERMES ANTIGEN; HYALURONIC ACID;

BONE MARROW STROMA CELL; CELL HOMING; CELLS; GENE EXPRESSION; GLYCOSYLATION; HEMATOPOIETIC STEM CELL; HUMAN; INTERNALIZATION; LEUKEMIA INITIATING CELL; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84934277764     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00235     Document Type: Review

References (332)

1. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature (1983) 304:30-4. doi: 10.1038/304030a0
2. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 65:13-24. doi:10.1016/0092-8674(91)90403-L
3. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol (2008) 18:260-7. doi:10.1016/j.semcancer.2008.03.015
4. Herrlich P, Zöller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today (1993) 14:395-9. doi:10.1016/0167-5699(93)90141-7
5. Ratajczak MZ. Cancer stem cells-normal stem cells "Jedi" that went over to the "dark side". Folia Histochem Cytobiol (2005) 43:175-81.
6. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer (2011) 11:254-67. doi:10.1038/nrc3023
7. Sales KM, Winslet MC, Seifalian AM. Stem cells and cancer: an overview. Stem Cell Rev (2007) 3:249-55. doi:10.1007/s12015-007-9002-0
8. Pei D. Regulation of pluripotency and reprogramming by transcription factors. J Biol Chem (2009) 284:3365-9. doi:10.1074/jbc. R800063200
9. Fábián A, Barok M, Vereb G, Szöllosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A (2009) 75:67-74. doi:10.1002/cyto.a.20690
10. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res (2008) 68:4018-21. doi:10.1158/0008-5472.CAN-07-6334
11. Conway AE, Lindgren A, Galic Z, Pyle AD, Wu H, Zack JA, et al. A pluripotency and self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells (2009) 27:18-28. doi:10.1634/stemcells.2008-0529
12. Wang JC. Good cells gone bad: the cellular origins of cancer. Trends Mol Med (2010) 16:145-51. doi:10.1016/j.molmed.2010.01.001
13. Alison MR, Guppy NJ, Lim SM, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol (2010) 222:335-44. doi:10.1002/path.2772
14. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A (1992) 89:12160-4. doi:10.1073/pnas.89.24.12160
15. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell (1989) 56:1057-62. doi:10.1016/0092-8674(89)90638-7
16. Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell (1989) 56:1063-72. doi:10.1016/0092-8674(89)90639-9
17. Idzerda RL, Carter WG, Nottenburg C, Wayner EA, Gallatin WM, St John T. Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc Natl Acad Sci U S A (1989) 86:4659-63. doi:10.1073/pnas.86.12.4659
18. Goldstein LA, Butcher EC. Identification of mRNA that encodes an alternative form of H-CAM (CD44) in lymphoid and nonlymphoid tissues. Immunogenetics (1990) 32:389-97. doi:10.1007/BF00241632
19. Greenfield B, Wang WC, Marquardt H, Piepkorn M, Wolff EA, Aruffo A, et al. Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44. J Biol Chem (1999) 274:2511-7. doi:10.1074/jbc.274.4.2511
20. Ishii S, Ford R, Thomas P, Nachman A, Steele G Jr, Jessup JM. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg Oncol (1993) 2:255-64. doi:10.1016/0960-7404(93)90015-Q
21. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol (1992) 116:817-25. doi:10.1083/jcb.116.3.817
22. Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng (2009) 11:177-202. doi:10.1146/annurev-bioeng-061008-124949
23. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 61:1303-13. doi:10.1016/0092-8674(90)90694-A
24. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol (1993) 122:257-64. doi:10.1083/jcb.122.1.257
25. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol (1993) 54:271-335. doi:10.1016/S0065-2776(08)60537-4
26. Toyama-Sorimachi N, Miyasaka M. A novel ligand for CD44 is sulfated proteoglycan. Int Immunol (1994) 6:655-60. doi:10.1093/intimm/6.4.655
27. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem (1993) 268:12235-8.
28. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol (2001) 155:755-62. doi:10.1083/jcb.200108159
29. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer (2005) 42:342-57. doi:10.1002/gcc.20156
30. Liu D, Sy MS. Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. J Immunol (1997) 159:2702-11.
31. Lokeshwar VB, Fregien N, Bourguignon LY. Ankyrin-binding domain of CD44(Gp85) is required for the expression of hyaluronic acid-mediated adhesion function. J Cell Biol (1994) 126:1099-109. doi:10.1083/jcb.126.4.1099
32. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol (2010) 11:276-87. doi:10.1038/nrm2866
33. Mori T, Kitano K, Terawaki S, Maesaki R, Fukami Y, Hakoshima T. Structural basis for CD44 recognition by ERM proteins. J Biol Chem (2008) 283:29602-12. doi:10.1074/jbc. M803606200
34. Stamenkovic I, Yu Q. Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci (2010) 11:471-84. doi:10.2174/138920310791824011
35. Oliferenko S, Paiha K, Harder T, Gerke V, Schwärzler C, Schwarz H, et al. Analysis of CD44-containing lipid rafts: recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol (1999) 146:843-54. doi:10.1083/jcb.146.4.843
36. Neame SJ, Isacke CM. The cytoplasmic tail of CD44 is required for basolateral localization in ephitelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts. J Cell Biol (1993) 121:1299-310. doi:10.1083/jcb.121.6.1299
37. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood (2011) 118:6743-51. doi:10.1182/blood-2011-07-343566
38. Róg T, Vattulainen I. Cholesterol, sphingolipids, and glycolipids: what do we know about their role in raft-like membranes? Chem Phys Lipids (2014) 184C:82-104. doi:10.1016/j.chemphyslip.2014.10.004
39. Föger N, Marhaba R, Zöller M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci (2001) 114:1169-78.
40. Slotte JP. Biological functions of sphingomyelins. Prog Lipid Res (2013) 52:424-37. doi:10.1016/j.plipres.2013.05.001
41. Ruiz P, Schwärzler C, Günthert U. CD44 isoforms during differentiation and development. Bioessays (1995) 17:17-24. doi:10.1002/bies.950170106
42. Zöller M. CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med (1995) 73:425-38.
43. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol (1995) 128:687-98. doi:10.1083/jcb.128.4.687
44. Orian-Rousseau V, Ponta H. Adhesion proteins meet receptors: a common theme? Adv Cancer Res (2008) 101:63-92. doi:10.1016/S0065-230X(08)00404-1
45. Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood (2009) 114:5236-44. doi:10.1182/blood-2009-04-219204
46. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell (2014) 14:342-56. doi:10.1016/j.stem.2014.01.009
47. Megaptche AP, Erb U, Büchler MW, Zöller M. CD44v10, osteopontin and lymphoma growth retardation by a CD44v10-specific antibody. Immunol Cell Biol (2014) 92:709-20. doi:10.1038/icb.2014.47
48. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (2013) 238:324-38. doi:10.1177/1535370213480714
49. Zou GM. Cancer stem cells in leukemia, recent advances. J Cell Physiol (2007) 213:440-4. doi:10.1002/jcp.21140
50. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene (2013) 32:5191-8. doi:10.1038/onc.2012.638
51. Tárnok A, Ulrich H, Bocsi J. Phenotypes of stem cells from diverse origin. Cytometry A (2010) 77:6-10. doi:10.1002/cyto.a.20844
52. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature (2009) 460:529-33. doi:10.1038/nature08199
53. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 464:1071-6. doi:10.1038/nature08975
54. Messaoudi-Aubert SE, Nicholls J, Maertens GN, Brookes S, Bernstein E, Peters G. Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor. Nat Struct Mol Biol (2010) 17:862-8. doi:10.1038/nsmb.1824
55. Kuçi S, Kuçi Z, Latifi-Pupovci H, Niethammer D, Handgretinger R, Schumm M, et al. Adult stem cells as an alternative source of multipotential (pluripotential) cells in regenerative medicine. Curr Stem Cell Res Ther (2009) 4:107-17. doi:10.2174/157488809788167427
56. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ, et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev (2009) 18:1093-108. doi:10.1089/scd.2009.0113
57. Cerdan C, Bhatia M. Novel roles for Notch, Wnt and Hedgehog in hematopoesis derived from human pluripotent stem cells. Int J Dev Biol (2010) 54:955-63. doi:10.1387/ijdb.103067cc
58. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 423:255-60. doi:10.1038/nature01572
59. Sancho-Martinez I, Baek SH, Izpisua Belmonte JC. Lineage conversion methodologies meet the reprogramming toolbox. Nat Cell Biol (2012) 14:892-9. doi:10.1038/ncb2567
60. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene (2002) 21:3414-21. doi:10.1038/sj.onc.1205400
61. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia (2014) 28:15-33. doi:10.1038/leu.2013.184
62. Katoh M. WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets (2008) 9:565-70. doi:10.2174/138945008784911750
63. Siapati EK, Papadaki M, Kozaou Z, Rouka E, Michali E, Savvidou I, et al. Proliferation and bone marrow engraftment of AML blasts is dependent on β-catenin signalling. Br J Haematol (2011) 152:164-74. doi:10.1111/j.1365-2141.2010.08471.x
64. Nagase H, Koh CS, Nakayama K. γ-Secretase-regulated signaling pathways, such as notch signaling, mediate the differentiation of hematopoietic stem cells, development of the immune system, and peripheral immune responses. Curr Stem Cell Res Ther (2011) 6:131-41. doi:10.2174/157488811795495459
65. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A (2010) 107:14229-34. doi:10.1073/pnas.0913574107
66. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol (2009) 10:116-25. doi:10.1038/nrm2621
67. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A (2010) 107:14235-40. doi:10.1073/pnas.1009798107
68. Hong SH, Kim KS, Oh IH. Concise review: exploring mirnas-toward a better understanding of hematopoiesis. Stem Cells (2015) 33:1-7. doi:10.1002/stem.1810
69. Lazare SS, Wojtowicz EE, Bystrykh LV, de Haan G. microRNAs in hematopoiesis. Exp Cell Res (2014) 329:234-8. doi:10.1016/j.yexcr.2014.08.033
70. Khalaj M, Tavakkoli M, Stranahan AW, Park CY. Pathogenic microRNA's in myeloid malignancies. Front Genet (2014) 5:361. doi:10.3389/fgene.2014.00361
71. Bottoni A, Calin GA. MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. Microrna (2014) 2:158-64. doi:10.2174/2211536602666131126002337
72. Agirre X, Martínez-Climent Já, Odero MD, Prósper F. Epigenetic regulation of miRNA genes in acute leukemia. Leukemia (2012) 26:395-403. doi:10.1038/leu.2011.344
73. Gounaris-Shannon S, Chevassut T. The role of miRNA in haematological malignancy. Bone Marrow Res (2013) 2013:269107. doi:10.1155/2013/269107
74. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem (2012) 287:32800-24. doi:10.1074/jbc. M111.308528
75. Liu H, Deng S, Zhao Z, Zhang H, Xiao J, Song W, et al. Oct4 regulates the miR-302 cluster in P19 mouse embryonic carcinoma cells. Mol Biol Rep (2011) 38:2155-60. doi:10.1007/s11033-010-0343-4
76. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology (2011) 141:2076-87. doi:10.1053/j.gastro.2011.08.050
77. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem (2009) 284:26533-46. doi:10.1074/jbc. M109.027466
78. Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia (2013) 15:281-95. doi:10.1593/neo.122010
79. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 467:86-90. doi:10.1038/nature09284
80. Hu H, Li Y, Gu J, Zhu X, Dong D, Yao J, et al. Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells. Leuk Lymphoma (2010) 51:694-701. doi:10.3109/10428191003596835
81. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res (2009) 7:168-79. doi:10.1158/1541-7786.MCR-08-0207
82. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 17:211-5. doi:10.1038/nm.2284
83. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res (2010) 3:28-47.
84. Liu L, Jiang Y, Zhang H, Greenlee AR, Han Z. Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by antibenzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Life Sci (2010) 86:192-8. doi:10.1016/j.lfs.2009.12.002
85. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, et al. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One (2010) 5:e9429. doi:10.1371/journal.pone.0009429
86. Jung T, Castellana D, Klingbeil P, Cuesta Hernández I, Vitacolonna M, Orlicky DJ, et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia (2009) 11:1093-105. doi:10.1593/neo.09822
87. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 18:74-82. doi:10.1038/nm.2577
88. Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J (2012) 279:2047-59. doi:10.1111/j.1742-4658.2012.08589.x
89. Wang SH, Zhou JD, He QY, Yin ZQ, Cao K, Luo CQ. MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. Int J Clin Exp Pathol (2014) 7:7131-41.
90. Rutnam ZJ, Yang BB. The non-coding 3' UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci (2012) 125(Pt 8):2075-85. doi:10.1242/jcs100818
91. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 10:202-10. doi:10.1038/ncb1681
92. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol (2007) 39:1432-49. doi:10.1016/j.biocel.2007.02.016
93. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci (2006) 119:2635-41. doi:10.1242/jcs.03053
94. Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 90:2217-33.
95. Ghazi-Visser L, Laman JD, Nagel S, van Meurs M, van Riel D, Tzankov A, et al. CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells. FASEB J (2013) 27:3683-701. doi:10.1096/fj.13-228809
96. Wittig BM, Johansson B, Zöller M, Schwärzler C, Günthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med (2000) 191:2053-64. doi:10.1084/jem.191.12.2053
97. Christ O, Günthert U, Haas R, Zöller M. Importance of CD44v7 isoforms for homing and seeding of hematopoietic progenitor cells. J Leukoc Biol (2001) 69:343-52.
98. Christ O, Günthert U, Schmidt DS, Zöller M. Allogeneic reconstitution after nonmyeloablative conditioning: mitigation of graft-versus-host and host-versus-graft reactivity by anti-CD44v6. J Leukoc Biol (2002) 71:33-46.
99. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol (2007) 23:675-88. doi:10.1146/annurev.cellbio.22.010305.104154
100. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 12:1175-80. doi:10.1038/nm1489
101. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 12:1167-74. doi:10.1038/nm1483
102. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med (1990) 171:477-88. doi:10.1084/jem.171.2.477
103. Mosaad YM. Hematopoietic stem cells: an overview. Transfus Apher Sci (2014) 51:68-82. doi:10.1016/j.transci.2014.10.016
104. Wolpert L. One hundred years of positional information. Trends Genet (1996) 12:359-64. doi:10.1016/S0168-9525(96)80019-9
105. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 66:4553-7. doi:10.1158/0008-5472.CAN-05-3986
106. Diaz-Flores L Jr, Madrid JF, Gutierrez R, Varela F, Alvarez-Argüelles H, Diaz-Flores L. Adult stem and transit-amplifying cell location. Histol Histopathol (2006) 21:995-1027.
107. Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell (2008) 132:598-611. doi:10.1016/j.cell.2008.01.038
108. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer (2007) 7:246-55. doi:10.1038/nrc2108
109. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells (1978) 4:7-25.
110. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature (2003) 425:836-41. doi:10.1038/nature02041
111. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp (1988) 136:42-60.
112. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol (2014) 164:767-78. doi:10.1111/bjh.12725
113. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood (2014) 125(2):249-60. doi:10.1182/blood-2014-04-572255
114. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell (2007) 1:685-97. doi:10.1016/j.stem.2007.10.020
115. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity (2006) 25:977-88. doi:10.1016/j.immuni.2006.10.016
116. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grünewald E, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 201:1781-91. doi:10.1084/jem.20041992
117. Askmyr M, Sims NA, Martin TJ, Purton LE. What is the true nature of the osteoblastic hematopoietic stem cell niche? Trends Endocrinol Metab (2009) 20:303-9. doi:10.1016/j.tem.2009.03.004
118. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 121:1109-21. doi:10.1016/j.cell.2005.05.026
119. Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia (2012) 26:54-62. doi:10.1038/leu.2011.236
120. Balduino A, Mello-Coelho V, Wang Z, Taichman RS, Krebsbach PH, Weeraratna AT, et al. Molecular signature and in vivo behavior of bone marrow endosteal and subendosteal stromal cell populations and their relevance to hematopoiesis. Exp Cell Res (2012) 318:2427-37. doi:10.1016/j.yexcr.2012.07.009
121. Stern R. Association between cancer and "acid mucopolysaccharides": an old concept comes of age, finally. Semin Cancer Biol (2008) 18:238-43. doi:10.1016/j.semcancer.2008.03.014
122. Khaldoyanidi SK, Goncharova V, Mueller B, Schraufstatter IU. Hyaluronan in the healthy and malignant hematopoietic microenvironment. Adv Cancer Res (2014) 123:149-89. doi:10.1016/B978-0-12-800092-2.00006-X
123. Szczepanek K, Kieda C, Cichy J. Differential binding of hyaluronan on the surface of tissue-specific endothelial cell lines. Acta Biochim Pol (2008) 55:35-42.
124. Winkler CW, Foster SC, Matsumoto SG, Preston MA, Xing R, Bebo BF, et al. Hyaluronan anchored to activated CD44 on central nervous system vascular endothelial cells promotes lymphocyte extravasation in experimental autoimmune encephalomyelitis. J Biol Chem (2012) 287:33237-51. doi:10.1074/jbc. M112.356287
125. Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. Nat Rev Mol Cell Biol (2009) 10:75-82. doi:10.1038/nrm2594
126. Itano N, Kimata K. Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol (2008) 18:268-74. doi:10.1016/j.semcancer.2008.03.006
127. Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci (2007) 80:1921-43. doi:10.1016/j.lfs.2007.02.037
128. Kuhn NZ, Tuan RS. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. J Cell Physiol (2010) 222:268-77. doi:10.1002/jcp.21940
129. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord (2005) 5:3-14. doi:10.2174/1568006053005056
130. Jung T, Gross W, Zöller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem (2011) 286:15862-74. doi:10.1074/jbc. M110.208421
131. Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol (2010) 26:89-114. doi:10.1146/annurev-cellbio-100109-104126
132. Weber GF. Molecular mechanisms of metastasis. Cancer Lett (2008) 270:181-90. doi:10.1016/j.canlet.2008.04.030
133. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res (1999) 59:219-26.
134. Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, et al. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer Res (2005) 65:686-91.
135. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med (2006) 12:657-64. doi:10.1038/nm1417
136. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res (2002) 62:2281-6.
137. Erb U, Megaptche AP, Gu X, Büchler MW, Zöller M. CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells. J Hematol Oncol (2014) 7:29. doi:10.1186/1756-8722-7-29
138. van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem (1999) 274:6499-506. doi:10.1074/jbc.274.10.6499
139. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 16:3074-86. doi:10.1101/gad.242602
140. Imanirad P, Dzierzak E. Hypoxia and HIFs in regulating the development of the hematopoietic system. Blood Cells Mol Dis (2013) 51:256-63. doi:10.1016/j.bcmd.2013.08.005
141. Poulos MG, Gars EJ, Gutkin MC, Kloss CC, Ginsberg M, Scandura JM, et al. Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. Exp Hematol (2014) 42:976.e-86.e. doi:10.1016/j.exphem.2014.08.003
142. Rosu-Myles M, Stewart E, Trowbridge J, Ito CY, Zandstra P, Bhatia M. A unique population of bone marrow cells migrates to skeletal muscle via hepatocyte growth factor/c-met axis. J Cell Sci (2005) 118:4343-52. doi:10.1242/jcs.02555
143. Sherman L, Wainwright D, Ponta H, Herrlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev (1998) 12:1058-71. doi:10.1101/gad.12.7.1058
144. Lee SK, Kim Y, Kim SS, Lee JH, Cho K, Lee SS, et al. Differential expression of cell surface proteins in human bone marrow mesenchymal stem cells cultured with or without basic fibroblast growth factor containing medium. Proteomics (2009) 9:4389-405. doi:10.1002/pmic.200900165
145. Berdiaki A, Nikitovic D, Tsatsakis A, Katonis P, Karamanos NK, Tzanakakis GN. bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. Biochim Biophys Acta (2009) 1790:1258-65. doi:10.1016/j.bbagen.2009.06.013
146. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res (2006) 66:18-23. doi:10.1158/0008-5472.CAN-04-3905
147. Pucci S, Mazzarelli P, Nucci C, Ricci F, Spagnoli L. G. CLU "in and out": looking for a link. Adv Cancer Res (2009) 105:93-113. doi:10.1016/S0065-230X(09)05006-4
148. Ratajczak MZ, Kim C, Ratajczak J, Janowska-Wieczorek A. Innate immunity as orchestrator of bone marrow homing for hematopoietic stem/progenitor cells. Adv Exp Med Biol (2013) 735:219-32. doi:10.1007/978-1-4614-4118-2_15
149. Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem (2009) 108:272-84. doi:10.1002/jcb.22248
150. Miletti-González KE, Murphy K, Kumaran MN, Ravindranath AK, Wernyj RP, Kaur S, et al. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem (2012) 287:18995-9007. doi:10.1074/jbc. M111.318774
151. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 13:35-48. doi:10.1101/gad.13.1.35
152. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res (2008) 68:5803-11. doi:10.1158/0008-5472.CAN-07-5889
153. Hill A, McFarlane S, Johnston PG, Waugh DJ. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett (2006) 237:1-9. doi:10.1016/j.canlet.2005.05.006
154. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 14:163-76.
155. Wilson TJ, Nannuru KC, Singh RK. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction. Mol Cancer Res (2009) 7:1224-33. doi:10.1158/1541-7786.MCR-09-0028
156. Chen Q, Yuan Y, Chen T. Morphology, differentiation and adhesion molecule expression changes of bone marrow mesenchymal stem cells from acute myeloid leukemia patients. Mol Med Rep (2014) 9:293-8. doi:10.3892/mmr.2013.1789
157. Almond A. Hyaluronan. Cell Mol Life Sci (2007) 64:1591-6. doi:10.1007/s00018-007-7032-z
158. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 4:528-39. doi:10.1038/nrc1391
159. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood (2005) 106:1901-10. doi:10.1182/blood-2005-04-1417
160. Liu J, Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol (2006) 3:359-65.
161. Lundell BI, Mccarthy JB, Kovach NL, Verfaillie CM. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia (1997) 11:822-9. doi:10.1038/sj.leu.2400653
162. Carstanjen D, Gross A, Kosova N, Fichtner I, Salama A. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factormobilized human hematopoietic progenitor cells. Transfusion (2005) 45:1192-200. doi:10.1111/j.1537-2995.2005.00172.x
163. Wierenga PK, Weersing E, Dontje B, de Haan G, van Os R. Differential role for very late antigen-5 in mobilization and homing of hematopoietic stem cells. Bone Marrow Transplant (2006) 38:789-97. doi:10.1038/sj.bmt.1705534
164. Marhaba R, Freyschmidt-Paul P, Zöller M. In vivo CD44-α4β1 complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol (2006) 36:3017-32. doi:10.1002/eji.200636158
165. Prosper F, Verfaillie CM. Regulation of hematopoiesis through adhesion receptors. J Leukoc Biol (2001) 69:307-16.
166. Ford CD, Greenwood J, Anderson J, Handrahan D, Petersen FB. Good and poor mobilizing patients differ in mobilized CD34+ cell adhesion molecule profiles. Transfusion (2004) 44:1769-73. doi:10.1111/j.0041-1132.2004.04035.x
167. Christ O, Kronenwett R, Haas R, Zöller M. Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells. Exp Hematol (2001) 29:380-90. doi:10.1016/S0301-472X(00)00674-3
168. Zohren F, Toutzaris D, Klärner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 111:3893-5. doi:10.1182/blood-2007-10-120329
169. Zöller M, Rajasagi M, Vitacolonna M, Luft T. Thymus repopulation after allogeneic reconstitution in hematological malignancies. Exp Hematol (2007) 35:1891-905. doi:10.1016/j.exphem.2007.08.005
170. Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med (2013) 19:1513-7. doi:10.1038/nm.3364
171. Singh R. (2011). CD44 as a Hematopoietic Stem Cell Marker. Ph. D. thesis, Faculty of Chemistry and Biosciences, KIT, Karlsruhe, Germany.
172. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science (2008) 322:1861-5. doi:10.1126/science.1164390
173. Khaldoyanidi S, Schnabel D, Föhr N, Zöller M. Functional activity of CD44 isoforms in haemopoiesis of the rat. Br J Haematol (1997) 96:31-45. doi:10.1111/j.1365-2141.1997.tb00001.x
174. Thirupathi P. (2014) Contribution of CD44v6 and CD44v7 to the Crosstalk Between Hematopoietic Stem Cells and the Bone Marrow Niche. Ph. D. thesis, Faculty of Chemistry and Biosciences, KIT, Karlsruhe, Germany.
175. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood (1976) 47:1031-9.
176. Koike K, Ogawa M, Ihle JN, Miyake T, Shimizu T, Miyajima A, et al. Recombinant murine granulocyte-macrophage (GM) colony-stimulating factor supports formation of GM and multipotential blast cell colonies in culture: comparison with the effects of interleukin-3. J Cell Physiol (1987) 131:458-64. doi:10.1002/jcp.1041310319
177. Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood (1992) 79:1193-200.
178. Liu F, Poursine-Laurent J, Link DC. Expression of the GCSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood (2000) 95:3025-31.
179. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood (2010) 116:4815-28. doi:10.1182/blood-2009-11-253534
180. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine induced mobilization. Blood (2009) 114:1331-9. doi:10.1182/blood-2008-10-184754
181. Goichberg P, Kalinkovich A, Borodovsky N, Tesio M, Petit I, Nagler A, et al. cAMP-induced PKCzeta activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors. Blood (2006) 107:870-9. doi:10.1182/blood-2005-03-0941
182. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 283:845-8. doi:10.1126/science.283.5403.845
183. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol (2002) 3:687-94. doi:10.1038/ni813
184. Bonig H, Papayannopoulou T. Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms. Methods Mol Biol (2012) 904:1-14. doi:10.1007/978-1-61779-943-3_1
185. Levesque JP, Liu F, Simmons PJ, Betsuyaku T, Senior RM, Pham C, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood (2004) 104:65-72. doi:10.1182/blood-2003-05-1589
186. Christopherson KWII, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/-mice. Exp Hematol (2003) 31:1126-34. doi:10.1016/j.exphem.2003.07.002
187. Levesque J, Takamatsu T, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood (2001) 98:1289-97. doi:10.1182/blood. V98.5.1289
188. Vagima Y, Avigdor A, Goichberg P, Shivtiel S, Tesio M, Kalinkovich A, et al. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest (2009) 119:492-503. doi:10.1172/JCI36541
189. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood (2004) 103:2981-9. doi:10.1182/blood-2003-10-3611
190. Ratajczak MZ, Reca R, Wysoczynski M, Kucia M, Baran JT, Allendorf DJ, et al. Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia (2004) 18:1482-90. doi:10.1038/sj.leu.2403446
191. Tjwa M, Janssens S, Carmeliet P. Plasmin therapy enhances mobilization of HPCs after G-CSF. Blood (2008) 112:4048-50. doi:10.1182/blood-2008-07-166587
192. Basak P, Chatterjee S, Das M, Das P, Pereira JA, Dutta RK, et al. Phenotypic alteration of bone marrow HSC and microenvironmental association in experimentally induced leukemia. Curr Stem Cell Res Ther (2010) 5:379-86. doi:10.2174/157488810793351677
193. Chellaiah MA, Ma T. Membrane localization of membrane type 1 matrix metalloproteinase by CD44 regulates the activation of pro-matrix metalloproteinase 9 in osteoclasts. Biomed Res Int (2013) 2013:302392. doi:10.1155/2013/302392
194. Raaijmakers MH. Regulating traffic in the hematopoietic stem cell niche. Haematologica (2010) 95:1439-41. doi:10.3324/haematol.2010.027342
195. Sipkins DA, Wei X, Wu JW, Runnels JM, Côté D, Means TK, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 435:969-73. doi:10.1038/nature03703
196. Lesley J, English NM, Gál I, Mikecz K, Day AJ, Hyman R. Hyaluronan binding properties of a CD44 chimera containing the link module of TSG-6. J Biol Chem (2002) 277:26600-8. doi:10.1074/jbc. M201068200
197. Katayama Y, Hidalgo A, Chang J, Peired A, Frenette PS. CD44 is a physiological E-selectin ligand on neutrophils. J Exp Med (2005) 201:1183-9. doi:10.1084/jem.20042014
198. Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci U S A (1995) 92:9647-51. doi:10.1073/pnas.92.21.9647
199. Lévesque JP, Leavesley DI, Niutta S, Vadas M, Simmons PJ. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med (1995) 181:1805-15. doi:10.1084/jem.181.5.1805
200. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med (1998) 188:465-74. doi:10.1084/jem.188.3.465
201. Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS. PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. Blood (2003) 102:2060-7. doi:10.1182/blood-2003-04-1212
202. Siegelman MH, Stanescu D, Estess P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J Clin Invest (2000) 105:683-91. doi:10.1172/JCI8692
203. Lamontagne CA, Grandbois M. PKC-induced stiffening of hyaluronan/CD44 linkage; local force measurements on glioma cells. Exp Cell Res (2008) 314:227-36. doi:10.1016/j.yexcr.2007.07.013
204. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 118:971-7. doi:10.1083/jcb.118.4.971
205. Oliferenko S, Kaverina I, Small JV, Huber LA. Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth. J Cell Biol (2000) 148:1159-64. doi:10.1083/jcb.148.6.1159
206. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol (2000) 20:1461-77. doi:10.1128/MCB.20.5.1461-1477.2000
207. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem (2003) 278:29420-34. doi:10.1074/jbc. M301885200
208. Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol (2008) 18:251-9. doi:10.1016/j.semcancer.2008.03.007
209. Singh V, Erb U, Zöller M. Cooperativity of CD44 and α4β1 in leukemia cell homing, migration, and survival offers a means for therapeutic attack. J Immunol (2013) 191:5304-16. doi:10.4049/jimmunol.1301543
210. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci (2004) 95:930-5. doi:10.1111/j.1349-7006.2004.tb03179.x
211. Nakamura H, Suenaga N, Taniwaki K, Matsuki H, Yonezawa K, Fujii M, et al. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res (2004) 64:876-82. doi:10.1158/0008-5472.CAN-03-3502
212. Sugahara KN, Hirata T, Tanaka T, Ogino S, Takeda M, Terasawa H, et al. Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Res (2008) 68:7191-9. doi:10.1158/0008-5472.CAN-07-6198
213. Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood (2014) 123:1361-71. doi:10.1182/blood-2013-11-538694
214. Ratajczak MZ, Kucia M, Majka M, Reca R, Ratajczak J. Heterogeneous populations of bone marrow stem cells-are we spotting on the same cells from the different angles? Folia Histochem Cytobiol (2004) 42:139-46.
215. Yang L, Wang L, Geiger H, Cancelas JA, Mo J, Zheng Y. Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc Natl Acad Sci U S A (2007) 104:5091-6. doi:10.1073/pnas.0610819104
216. Vaiselbuh SR, Edelman M, Lipton JM, Liu JM. Ectopic human mesenchymal stem cell-coated scaffolds in NOD/SCID mice: an in vivo model of the leukemia niche. Tissue Eng Part C Methods (2010) 16:1523-31. doi:10.1089/ten.tec.2010.0179
217. Tavor S, Petit I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol (2010) 20:178-85. doi:10.1016/j.semcancer.2010.07.001
218. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res (1997) 71:241-319.
219. Yamamura K, Ohishi K, Katayama N, Kato K, Shibasaki T, Sugimoto Y. Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and-negative human hematopoietic progenitors. Cancer Sci (2007) 98:1597-603. doi:10.1111/j.1349-7006.2007.00566.x
220. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem (2006) 99:690-705. doi:10.1002/jcb.21043
221. de Barros AP, Takiya CM, Garzoni LR, Leal-Ferreira ML, Dutra HS, Chiarini LB, et al. Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model. PLoS One (2010) 5:e9093. doi:10.1371/journal.pone.0009093
222. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood (2005) 106:1232-9. doi:10.1182/blood-2004-11-4422
223. Lee H, Ratajczak MZ. Innate immunity: a key player in the mobilization of hematopoietic stem/progenitor cells. Arch Immunol Ther Exp (2009) 57:269-78. doi:10.1007/s00005-009-0037-6
224. Asosingh K, Günthert U, Bakkus MH, De Raeve H, Goes E, Van Riet I, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res (2000) 60:3096-104.
225. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 4:33-45. doi:10.1038/nrm1004
226. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol (2004) 35:211-31. doi:10.1023/B:HIJO.0000032354.94213.69
227. Pap E, Pállinger E, Pásztói M, Falus A. Highlights of a new type of intercellular communication: microvesicle-based information transfer. Inflamm Res (2009) 58:1-8. doi:10.1007/s00011-008-8210-7
228. Stanley S. Biological nanoparticles and their influence on organisms. Curr Opin Biotechnol (2014) 28:69-74. doi:10.1016/j.copbio.2013.11.014
229. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem (2013) 288:34343-51. doi:10.1074/jbc. M113.480822
230. Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles-diagnostic and therapeutic implications (review). Int J Oncol (2015) 46:17-27. doi:10.3892/ijo.2014.2712
231. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 20:847-56. doi:10.1038/sj.leu.2404132
232. Okuyama K, Ogata J, Yamakawa N, Chanda B, Kotani A. Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis. Int J Hematol (2014) 99:553-60. doi:10.1007/s12185-014-1564-4
233. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res (2011) 17:4936-41. doi:10.1158/1078-0432.CCR-10-1499
234. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell (2004) 118:149-61. doi:10.1016/j.cell.2004.07.004
235. Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood (2008) 111:492-503. doi:10.1182/blood-2007-07-075168
236. Bourguignon LY, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem (2002) 277:39703-12. doi:10.1074/jbc. M204320200
237. Basoni C, Reuzeau E, Croft D, Génot E, Kramer IM. CD44 and TGFbeta1 synergise to induce expression of a functional NADPH oxidase in promyelocytic cells. Biochem Biophys Res Commun (2006) 343:609-16. doi:10.1016/j.bbrc.2006.03.003
238. Robin C, Durand C. The roles of BMP and IL-3 signaling pathways in the control of hematopoietic stem cells in the mouse embryo. Int J Dev Biol (2010) 54:1189-200. doi:10.1387/ijdb.093040cr
239. Pimanda JE, Ottersbach K, Knezevic K, Kinston S, Chan WY, Wilson NK, et al. Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U S A (2007) 104:17692-7. doi:10.1073/pnas.0707045104
240. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 425:841-6. doi:10.1038/nature02040
241. Marshall CJ, Sinclair JC, Thrasher AJ, Kinnon C. Bone morphogenetic protein 4 modulates c-Kit expression and differentiation potential in murine embryonic aorta-gonad-mesonephros haematopoiesis in vitro. Br J Haematol (2007) 139:321-30. doi:10.1111/j.1365-2141.2007.06795.x
242. Peterson RS, Andhare RA, Rousche KT, Knudson W, Wang W, Grossfield JB, et al. CD44 modulates Smad1 activation in the BMP-7 signaling pathway. J Cell Biol (2004) 166:1081-91. doi:10.1083/jcb.200402138
243. Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y. Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem Biophys Res Commun (2010) 394:317-22. doi:10.1016/j.bbrc.2010.02.175
244. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Månsson R, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell (2007) 1:671-84. doi:10.1016/j.stem.2007.10.008
245. Kashiwakura I, Teramachi T, Kakizaki I, Takagi Y, Takahashi TA, Takagaki K. The effects of glycosaminoglycans on thrombopoietin-induced megakaryocytopoiesis. Haematologica (2006) 91:445-51.
246. Cain CJ, Manilay JO. Hematopoietic stem cell fate decisions are regulated by Wnt antagonists: comparisons and current controversies. Exp Hematol (2013) 41:3-16. doi:10.1016/j.exphem.2012.09.006
247. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev (1997) 11:3286-305. doi:10.1101/gad.11.24.3286
248. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature (2000) 407:535-8. doi:10.1038/35035124
249. Willert K, Nusse R. β-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev (1998) 8:95-102. doi:10.1016/S0959-437X(98)80068-3
250. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 17:9-26. doi:10.1016/j.devcel.2009.06.016
251. Stathopoulos A, Iber D. Studies of morphogens: keep calm and carry on. Development (2013) 140:4119-24. doi:10.1242/dev.095141
252. MacDonald BT, Adamska M, Meisler MH. Hypomorphic expression of Dkk1 in the doubleridge mouse: dose dependence and compensatory interactions with Lrp6. Development (2004) 11:2543-52. doi:10.1242/dev.01126
253. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature (2002) 6889:664-7. doi:10.1038/nature756
254. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell (2008) 2:274-83. doi:10.1016/j.stem.2008.01.003
255. Yu X, Alder JK, Chun JH, Friedman AD, Heimfeld S, Cheng L, et al. HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells (2006) 4:876-88. doi:10.1634/stemcells.2005-0598
256. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol (2005) 6:314-22. doi:10.1038/ni1164
257. Schmitt M, Metzger M, Gradl D, Davidson G, Orian-Rousseau V. CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ (2014) 22(4):677-89. doi:10.1038/cdd.2014.156
258. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood (2009) 114:49-59. doi:10.1182/blood-2009-01-197988
259. Yokasaki Y, Sheppard D. Mapping of the cryptic integrin-binding site in osteopontin suggests a new mechanism by which thrombin can regulate inflammation and tissue repair. Trends Cardiovasc Med (2000) 10:155-9. doi:10.1016/S1050-1738(00)00055-4
260. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One (2011) 6:e24217. doi:10.1371/journal.pone.0024217
261. Ara T, Nakamura Y, Egawa T, Sugiyama T, Abe K, Kishimoto T, et al. Impaired colonization of the gonads by primordial germ cells in mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). Proc Natl Acad Sci U S A (2003) 100:5319-23. doi:10.1073/pnas.0730719100
262. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 393:595-9. doi:10.1038/31269
263. Lin ML, Lu YC, Chen HY, Lee CC, Chung JG, Chen SS. Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1a-induced invasion of human esophageal carcinoma cells. Mol Carcinog (2014) 53:360-79. doi:10.1002/mc.21984
264. Ratajczak MZ, Lee H, Wysoczynski M, Wan W, Marlicz W, Laughlin MJ, et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia (2010) 24:976-85. doi:10.1038/leu.2010.53
265. Fuchs K, Hippe A, Schmaus A, Homey B, Sleeman JP, Orian-Rousseau V. Opposing effects of high-and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis (2013) 4:e819. doi:10.1038/cddis.2013.364
266. Ellis SL, Grassinger J, Jones A, Borg J, Camenisch T, Haylock D, et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood (2011) 118:1516-24. doi:10.1182/blood-2010-08-303800
267. Schraufstatter IU, Serobyan N, Loring J, Khaldoyanidi SK. Hyaluronan is required for generation of hematopoietic cells during differentiation of human embryonic stem cells. J Stem Cells (2010) 5:9-21.jsc.2010.5.1.9
268. Haylock DN, Nilsson SK. Stem cell regulation by the hematopoietic stem cell niche. Cell Cycle (2005) 4:1353-5. doi:10.4161/cc.4.10.2056
269. Wang A, de la Motte C, Lauer M, Hascall V. Hyaluronan matrices in pathobiological processes. FEBS J (2011) 278:1412-8. doi:10.1111/j.1742-4658.2011.08069.x
270. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell (2010) 7:150-61. doi:10.1016/j.stem.2010.07.007
271. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell (2013) 13:285-99. doi:10.1016/j.stem.2013.06.009
272. Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell (2011) 9:298-310. doi:10.1016/j.stem.2011.09.010
273. Zou P, Yoshihara H, Hosokawa K, Tai I, Shinmyozu K, Tsukahara F, et al. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell (2011) 9:247-61. doi:10.1016/j.stem.2011.07.003
274. Mantel C, Messina-Graham S, Broxmeyer HE. Upregulation of nascent mitochondrial biogenesis in mouse hematopoietic stem cells parallels upregulation of CD34 and loss of pluripotency: a potential strategy for reducing oxidative risk in stem cells. Cell Cycle (2010) 9:2008-17. doi:10.4161/cc.9.10.11733
275. Darzynkiewicz Z, Balazs EA. Genome integrity, stem cells and hyaluronan. Aging (2012) 4:78-88.
276. Simsek T, Kocabas F, Zheng J, Deberardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell (2010) 7:380-90. doi:10.1016/j.stem.2010.07.011
277. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 30:393-402. doi:10.1016/j.molcel.2008.04.009
278. Wheaton WW, Chandel NS. Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol (2011) 300:C385-93. doi:10.1152/ajpcell.00485.2010
279. Miharada K, Karlsson G, Rehn M, Rörby E, Siva K, Cammenga J, et al. Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell (2011) 9:330-44. doi:10.1016/j.stem.2011.07.016
280. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell (2010) 7:391-402. doi:10.1016/j.stem.2010.06.020
281. Liu J, Cao L, Chen J, Song S, Lee IH, Quijano C, et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature (2009) 459:387-92. doi:10.1038/nature08040
282. Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, et al. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol (2013) 15:533-43. doi:10.1038/ncb2730
283. Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell (2014) 14:357-69. doi:10.1016/j.stem.2014.01.005
284. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr (2007) 39:223-9. doi:10.1007/s10863-007-9080-3
285. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 4:891-9. doi:10.1038/nrc1478
286. Das R, Baker D. Macromolecular modeling with rosetta. Annu Rev Biochem (2008) 77:363-82. doi:10.1146/annurev.biochem.77.062906.171838
287. Preston M, Sherman LS. Neural stem cell niches: roles for the hyaluronan-based extracellular matrix. Front Biosci (2011) 3:1165-79. doi:10.2741/218
288. Orian-Rousseau V, Sleeman J. CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals. Adv Cancer Res (2014) 123:231-54. doi:10.1016/B978-0-12-800092-2.00009-5
289. Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol (2008) 18:244-50. doi:10.1016/j.semcancer.2008.03.009
290. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg (2006) 132:771-8. doi:10.1001/archotol.132.7.771
291. Sherman LS, Rizvi TA, Karyala S, Ratner N. CD44 enhances neuregulin signaling by Schwann cells. J Cell Biol (2000) 150:1071-84. doi:10.1083/jcb.150.5.1071
292. Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem (2005) 280:8875-83. doi:10.1074/jbc. M410882200
293. Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S. Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem (2009) 284:12432-46. doi:10.1074/jbc. M806772200
294. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem (2007) 282:19426-41. doi:10.1074/jbc. M610054200
295. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell (2007) 18:76-83. doi:10.1091/mbc. E06-08-0674
296. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate (2014) 74:602-17. doi:10.1002/pros.22775
297. Hasenauer S, Malinger D, Koschut D, Pace G, Matzke A, von Au A, et al. Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins. PLoS One (2013) 8:e62357. doi:10.1371/journal.pone.0062357
298. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G II, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 69:1951-7. doi:10.1158/0008-5472.CAN-08-2023
299. Porsch H, Mehic M, Olofsson B, Heldin P, Heldin CH. Platelet-derived growth factor β-receptor, transforming growth factor β type I receptor, and CD44 protein modulate each other's signaling and stability. J Biol Chem (2014) 289:19747-57. doi:10.1074/jbc. M114.547273
300. Mielgo A, van Driel M, Bloem A, Landmann L, Günthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ (2006) 13:465-77. doi:10.1038/sj.cdd.4401763
301. Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM. Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. Cancer Res (2007) 67:6760-7. doi:10.1158/0008-5472.CAN-07-0026
302. Kivisaari AK, Kallajoki M, Ala-aho R, McGrath JA, Bauer JW, Königová R, et al. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol (2010) 163:726-35. doi:10.1111/j.1365-2133.2010.09924.x
303. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, α4β1, CD44 and MMP-9. Br J Haematol (2011) 154:216-22. doi:10.1111/j.1365-2141.2011.08725.x
304. Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, Albar JP, García-Marco JA, García-Pardo A. A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells. J Biol Chem (2014) 289:15340-9. doi:10.1074/jbc. M114.559187
305. Zarzynska JM. Two FACes of TGF-beta1 in breast cancer. Mediators Inflamm (2014) 2014:141747. doi:10.1155/2014/141747
306. Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem (2010) 285:4060-73. doi:10.1074/jbc. M109.056523
307. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res (2010) 70:2455-64. doi:10.1158/0008-5472.CAN-09-2505
308. Goldie SJ, Mulder KW, Tan DW, Lyons SK, Sims AH, Watt FM. FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. Cancer Res (2012) 72:3424-36. doi:10.1158/0008-5472.CAN-12-0423
309. Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen Q, et al. CD44 acts through RhoA to regulate YAP signaling. Cell Signal (2014) 26:2504-13. doi:10.1016/j.cellsig.2014.07.031
310. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, et al. Interplay of mevalonate and hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A (2014) 111:E89-98. doi:10.1073/pnas.1319190110
311. Zhao H, Tanaka T, Mitlitski V, Heeter J, Balazs EA, Darzynkiewicz Z. Protective effect of hyaluronate on oxidative DNA damage in WI-38 and A549 cells. Int J Oncol (2008) 32:1159-67.
312. Thankamony SP, Knudson W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. J Biol Chem (2006) 281:34601-9. doi:10.1074/jbc. M601530200
313. Campo GM, Avenoso A, Campo S, D'Ascola A, Ferlazzo AM, Calatroni A. Reduction of DNA fragmentation and hydroxyl radical production by hyaluronic acid and chondroitin-4-sulphate in iron plus ascorbate-induced oxidative stress in fibroblast cultures. Free Radic Res (2004) 38:601-11. doi:10.1080/10715760410001694017
314. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K. Stem cell marker (Nanog) and Stat-3 signaling promote microRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene (2012) 31:149-60. doi:10.1038/onc.2011.222
315. Kathawala RJ, Gupta P, Ashby CR Jr, Chen Z. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat (2014) pii:78-78. doi:10.1016/j.drup.2014.11.002
316. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem (2005) 280:20310-5. doi:10.1074/jbc. M500737200
317. Liu CM, Chang CH, Yu CH, Hsu CC, Huang LL. Hyaluronan substratum induces multidrug resistance in human mesenchymal stem cells via CD44 signaling. Cell Tissue Res (2009) 336:465-75. doi:10.1007/s00441-009-0780-3
318. Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem (2009) 284:2657-71. doi:10.1074/jbc. M806708200
319. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res (2009) 69:4992-8. doi:10.1158/0008-5472.CAN-09-0143
320. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target (2012) 20:561-73. doi:10.3109/1061186X.2012.702767
321. Midgley AC, Bowen T. Analysis of human hyaluronan synthase gene transcriptional regulation and downstream hyaluronan cell surface receptor mobility in myofibroblast differentiation. Methods Mol Biol (2015) 1229:605-18. doi:10.1007/978-1-4939-1714-3_47
322. Sebens S, Schafer H. The tumor stroma as mediator of drug resistance-a potential target to improve cancer therapy? Curr Pharm Biotechnol (2012) 13:2259-72. doi:10.2174/138920112802501999
323. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res (2014) 123:35-65. doi:10.1016/B978-0-12-800092-2.00002-2
324. Skandalis SS, Gialeli C, Theocharis AD, Karamanos NK. Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer. Adv Cancer Res (2014) 123:277-317. doi:10.1016/B978-0-12-800092-2.00011-3
325. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia (2009) 23:25-42. doi:10.1038/leu.2008.246
326. ten Cate B, de Bruyn M, Wei Y, Bremer E, Helfrich W. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets (2010) 11:95-110. doi:10.2174/138945010790031063
327. Tabarkiewicz J, Giannopoulos K. Definition of a target for immunotherapy and results of the first peptide vaccination study in chronic lymphocytic leukemia. Transplant Proc (2010) 42:3293-6. doi:10.1016/j.transproceed.2010.07.022
328. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene (2011) 30:1009-19. doi:10.1038/onc.2010.511
329. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 29:591-9. doi:10.1200/JCO.2010.31.0904
330. Brayer JB, Pinilla-Ibarz J. Developing strategies in the immunotherapy of leukemias. Cancer Control (2013) 20:49-59.
331. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol (1998) 176:206-15. doi:10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3
332. D'Arena G, Calapai G, Deaglio S. Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. Expert Opin Ther Pat (2014) 24:821-8. doi:10.1517/13543776.2014.915942